Pharmacology
Covid-19
A promising antiviral
Molnupiravir reduced COVID-19’s hospitalization and death rate by nearly half in a phase 3 clinical trial of people with mild to moderate infections
By Redação
COVID-19
Still too soon for booster doses
An international group of scientists argued against the idea of giving the majority of the population COVID-19 vaccine booster doses
By Redação
Physics/Chemistry
Free passage through the skin
Simulations indicate that applying an electric field stimulates the formation of "blisters" that turn the epidermis into a gateway for drugs to enter the body
By Tiago Jokura
COVID-19
ButanVac clinical trials begin
ButanVac, the vaccine candidate that will be produced by the Butantan Institute entirely in Brazil with no need to import any ingredients, has begun clinical trials
By Redação
Pharmacology
New Alzheimer’s drug sparks controversy
A new compound designed to fight Alzheimer's disease is causing controversy
By Redação
COVID-19
New clues about blood clots linked to the AstraZeneca vaccine
A step has been taken towards explaining why the vaccine developed by the pharmaceutical company AstraZeneca can very rarely lead to the formation of blood clots
By Redação
COVID-19
New vaccines on the way
Butantan Institute and federal government plan to start human trials of two vaccine candidates in the coming months
By Marcos Pivetta and Ricardo Zorzetto
Butantan – 120 Years
Constant metamorphosis
Scientific discoveries call attention to quality control in the production of serums and vaccines
Entrepreneurship
Supply-side research constraints
Small local manufacturers struggle to gain foothold in Brazilian scientific supplies market
Butantan – 120 years
Renewed momentum
The São Paulo institute strengthened itself, mobilized competencies, and integrated teams to face the pandemic
COVID-19
Yes to the vaccine
On January 18, FAPESP started the #vacinasim (“yesvaccine”) social media campaign to reinforce public confidence in their safety and effectiveness
By Redação
COVID-19
Distribution challenges
Governments need to work with pharmaceutical and logistics companies to overcome obstacles to start the SARS-CoV-2 immunization campaign
By Tiago Jokura
COVID-19
Butantan develops serum for the novel coronavirus
The Butantan Institute has completed development of a serum to combat SARS-CoV-2
By Redação
COVID-19
Unequal access
Even before efficacy data for the vaccine candidates was released, it was clear that there will not be enough supply to immunize the entire global population before the end of next year
By Redação
COVID-19
Australia gives up on vaccine candidate
A vaccine being developed by the University of Queensland and biotechnology company CSL, both from Australia, is the first of more than 200 candidates to be discarded
By Redação
COVID-19
Vaccines and sharks
A compound extracted from the livers of sharks is used in five coronavirus vaccine candidates
By Redação